210 related articles for article (PubMed ID: 15693135)
21. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.
Hamann PR; Hinman LM; Hollander I; Beyer CF; Lindh D; Holcomb R; Hallett W; Tsou HR; Upeslacis J; Shochat D; Mountain A; Flowers DA; Bernstein I
Bioconjug Chem; 2002; 13(1):47-58. PubMed ID: 11792178
[TBL] [Abstract][Full Text] [Related]
22. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
23. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.
Mansfield E; Amlot P; Pastan I; FitzGerald DJ
Blood; 1997 Sep; 90(5):2020-6. PubMed ID: 9292538
[TBL] [Abstract][Full Text] [Related]
24. Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.
Newton DL; Ryback SM
Expert Opin Biol Ther; 2001 Nov; 1(6):995-1003. PubMed ID: 11728231
[TBL] [Abstract][Full Text] [Related]
25. Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment.
Krauss J; Arndt MA; Martin AC; Liu H; Rybak SM
Protein Eng; 2003 Oct; 16(10):753-9. PubMed ID: 14600205
[TBL] [Abstract][Full Text] [Related]
26. Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.
Sharkey RM; Govindan SV; Cardillo TM; Goldenberg DM
Mol Cancer Ther; 2012 Jan; 11(1):224-34. PubMed ID: 22039078
[TBL] [Abstract][Full Text] [Related]
27. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
28. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Li D; Poon KA; Yu SF; Dere R; Go M; Lau J; Zheng B; Elkins K; Danilenko D; Kozak KR; Chan P; Chuh J; Shi X; Nazzal D; Fuh F; McBride J; Ramakrishnan V; de Tute R; Rawstron A; Jack AS; Deng R; Chu YW; Dornan D; Williams M; Ho W; Ebens A; Prabhu S; Polson AG
Mol Cancer Ther; 2013 Jul; 12(7):1255-65. PubMed ID: 23598530
[TBL] [Abstract][Full Text] [Related]
29. The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies.
Li JL; Shen GL; Ghetie MA; May RD; Till M; Ghetie V; Uhr JW; Janossy G; Thorpe PE; Amlot P
Cell Immunol; 1989 Jan; 118(1):85-99. PubMed ID: 2463099
[TBL] [Abstract][Full Text] [Related]
30. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.
Mattes MJ; Shih LB; Govindan SV; Sharkey RM; Ong GL; Xuan H; Goldenberg DM
Int J Cancer; 1997 May; 71(3):429-35. PubMed ID: 9139880
[TBL] [Abstract][Full Text] [Related]
31. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
[TBL] [Abstract][Full Text] [Related]
32. The amino-terminal immunoglobulin-like domain of sialoadhesin contains the sialic acid binding site. Comparison with CD22.
Nath D; van der Merwe PA; Kelm S; Bradfield P; Crocker PR
J Biol Chem; 1995 Nov; 270(44):26184-91. PubMed ID: 7592823
[TBL] [Abstract][Full Text] [Related]
33. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
34. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
[TBL] [Abstract][Full Text] [Related]
35. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
[TBL] [Abstract][Full Text] [Related]
36. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics.
Hursey M; Newton DL; Hansen HJ; Ruby D; Goldenberg DM; Rybak SM
Leuk Lymphoma; 2002 May; 43(5):953-9. PubMed ID: 12148905
[TBL] [Abstract][Full Text] [Related]
37. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
Lindén O; Hindorf C; Tennvall J; Segrén S; Wingardh K; Strand SE
Cancer; 2002 Feb; 94(4 Suppl):1270-4. PubMed ID: 11877756
[TBL] [Abstract][Full Text] [Related]
38. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
39. Specific thermal ablation of tumor cells using single-walled carbon nanotubes targeted by covalently-coupled monoclonal antibodies.
Marches R; Chakravarty P; Musselman IH; Bajaj P; Azad RN; Pantano P; Draper RK; Vitetta ES
Int J Cancer; 2009 Dec; 125(12):2970-7. PubMed ID: 19536775
[TBL] [Abstract][Full Text] [Related]
40. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]